Last updated on August 2020

Phase 1 Study Evaluating VT1021 in Patients With Advanced Solid Tumors

Brief description of study

This study is an an open-label Phase I trial of VT1021 in patients with advanced solid tumors. Patients must have recurrent or advanced cancer (i.e., solid tumors) for which standard therapy offers no curative potential.

Detailed Study Description

This is an open-label Phase I study of VT1021 in patients with advanced solid tumors. The study will include a Dose Escalation Phase and a Dose Expansion Phase. Upon determination of the Recommended Phase 2 Dose in the Dose Escalation Phase, the Dose Expansion Phase will be opened. The Dose Expansion Phase will include cohorts in ovarian, pancreatic, triple negative breast cancer, glioblastoma and CD36-high patients in order to confirm the tolerability of VT1021 against specific tumor types.

Clinical Study Identifier: NCT03364400

Find a site near you

Start Over


San Antonio, TX United States
  Connect »

Horizon Oncology Center

Lafayette, IN United States
  Connect »

Florida Cancer Specialists

Sarasota, FL United States
  Connect »

The Johns Hopkins Hospital

Baltimore, MD United States
  Connect »

Beth Israel

Boston, MA United States
  Connect »

Cleveland Clinic

Cleveland, OH United States
  Connect »

University of Oklahoma

Oklahoma City, OK United States
  Connect »

MD Anderson Cancer Center

Houston, TX United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.